The estimated Net Worth of Omar Khwaja is at least $4.66 Milión dollars as of 21 May 2021. Omar Khwaja owns over 3,516 units of Voyager Therapeutics Inc stock worth over $756,797 and over the last 6 years he sold VYGR stock worth over $85,766. In addition, he makes $3,815,770 as Chief Medical Officer and Head of Research and Development at Voyager Therapeutics Inc.
Omar has made over 3 trades of the Voyager Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 3,516 units of VYGR stock worth $14,169 on 21 May 2021.
The largest trade he's ever made was selling 3,516 units of Voyager Therapeutics Inc stock on 21 May 2021 worth over $14,169. On average, Omar trades about 1,499 units every 52 days since 2019. As of 21 May 2021 he still owns at least 120,509 units of Voyager Therapeutics Inc stock.
You can see the complete history of Omar Khwaja stock trades at the bottom of the page.
Dr. Omar Khwaja M.D. Ph.D. serves as Chief Medical Officer and Head of Research and Development of the Company since May 2019. Dr. Khwaja was previously the Global Head of Neuroscience Translational Medicine and Global Head of Rare Diseases at Roche, where he worked for seven years from January 2012 to March 2019. Prior to Roche, Dr. Khwaja was Director of the Clinical Neurogenetics Program at Boston Children’s Hospital and on the faculty of Harvard Medical School from 2006 to 2012. Dr. Khwaja is a Member of the Royal College of Physicians of the United Kingdom and a Member of the Royal College of Pediatrics and Child Health. Dr. Khwaja trained in pediatrics and clinical genetics in London, UK and Melbourne, Australia, and completed his neurology training at Massachusetts General Hospital and Boston Children’s Hospital, where he was Chief Resident. Dr. Khwaja received a B.A, a M.A. in Developmental Biology and Neuroscience, a M.D. and a Ph.D. in Human Molecular Genetics, each from the University of Cambridge, Cambridge, UK.
As the Chief Medical Officer and Head of Research and Development of Voyager Therapeutics Inc, the total compensation of Omar Khwaja at Voyager Therapeutics Inc is $3,815,770. There are no executives at Voyager Therapeutics Inc getting paid more.
Omar Khwaja is 50, he's been the Chief Medical Officer and Head of Research and Development of Voyager Therapeutics Inc since 2019. There are 10 older and 4 younger executives at Voyager Therapeutics Inc. The oldest executive at Voyager Therapeutics Inc is Dr. Steven M. Paul M.D., 70, who is the Exec. Science Advisor & Director.
Omar's mailing address filed with the SEC is C/O VOYAGER THERAPEUTICS, INC.,, 75 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 9 years, insiders at Voyager Therapeutics Inc have traded over $22,599,571 worth of Voyager Therapeutics Inc stock and bought 9,198,716 units worth $93,782,260 . The most active insiders traders include Sanofi, Capital, Llc Eco R1 a Biosciences Inc Neurocrine. On average, Voyager Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $966,976. The most recent stock trade was executed by Robin Swartz on 2 April 2024, trading 1,357 units of VYGR stock currently worth $13,407.
voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.
Voyager Therapeutics Inc executives and other stock owners filed with the SEC include: